Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro

被引:130
|
作者
Alyaudtin, RN
Reichel, A
Löbenberg, R
Ramge, P
Kreuter, J
Begley, DJ
机构
[1] Kings Coll London, Ctr Res Neurosci, London SE1 1UL, England
[2] Goethe Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany
[3] Sechnov Med Acad, Dept Pharmacol, Moscow 119881, Russia
关键词
nanoparticles; blood-brain barrier; drug delivery; dalargin;
D O I
10.3109/10611860108997929
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poly(butylcyanoacrylate) nanoparticles were produced by emulsion polymerisation and used either uncoated or overcoated with polysorbate 80 (Tween (R) 80). [H-3]-dalargin bound to nanoparticles overcoated with polysorbate 80 or in the form of saline solution was injected into mice and the brain concentrations of radioactivity determined. Statistically significant, three-fold higher brain concentrations with the nanoparticle preparations were obtained after 45 minutes, the time of greatest pharmacological response assessed as analgesia in previous experiments. In addition the brain inulin spaces in rats and the uptake of fluoresceine isothio-cyanate labelled nanoparticles in immortalised rat cerebral endothelial cells, (RBE4) were measured. The inulin spaces after i.v. injection of polysorbate 80-coated nanoparticles were significantly increased by 1% compared to controls. This is interpreted as indicating that there is no large scale opening of the tight junctions of the brain endothelium by the polysorbate 80-coated nanoparticles. In in vitro experiments endocytic uptake of fluorescent nanoparticles by RBE4 cells was only observed after polysorbate 80-overcoating, not with uncoated particles. These results further support the hypothesis that the mechanism of blood-brain barrier transport of drugs by polysorbate 80-coated nanoparticles is one of endocytosis followed by possible transcytosis. The experiments were conducted in several laboratories as part of an EEC/INTAS collaborative program. For various procedural and regulatory reasons this necessitated the use of both rats and mice as experimental animals. The brain endothelial cell line used for the in vitro studies is the rat RBE4.
引用
收藏
页码:209 / +
页数:16
相关论文
共 50 条
  • [31] Nanoparticles and the blood-brain barriers in vitro: Carriers as well as barrier modulators
    Galla, H.
    Cramer, S.
    Rempe, R. G.
    MOLECULAR BIOLOGY OF THE CELL, 2014, 25
  • [32] An in vitro and in vivo study of peptide-functionalized nanoparticles for brain targeting: The importance of selective blood-brain barrier uptake
    Bode, Gerard H.
    Coue, Gregory
    Freese, Christian
    Pickl, Karin E.
    Sanchez-Purra, Maria
    Albaiges, Berta
    Borros, Salvador
    van Winden, Ewoud C.
    Tziveleka, Leto-Aikaterini
    Sideratou, Zili
    Engbersen, Johan F. J.
    Singh, Smriti
    Albrecht, Krystyna
    Groll, Juergen
    Moeller, Martin
    Poetgens, Andy J. G.
    Schmitzk, Christoph
    Froehlich, Eleonore
    Grandfils, Christian
    Sinner, Frank M.
    Kirkpatrick, C. James
    Steinbusch, Harry W. M.
    Frank, Hans-Georg
    Unger, Ronald E.
    Martinez-Martinez, Pilar
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2017, 13 (03) : 1289 - 1300
  • [33] Drug transport to the brain: Comparison between in vitro and in vivo models of the blood-brain barrier
    Dehouck, MP
    Dehouck, B
    Schluep, C
    Lemaire, M
    Cecchelli, R
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 3 (06) : 357 - 365
  • [34] Circulating low-molecular-weight (poly)phenol metabolites in the brain: unveiling in vitro and in vivo blood-brain barrier transport
    Carecho, Rafael
    Marques, Daniela
    Carregosa, Diogo
    Masuero, Domenico
    Garcia-Aloy, Mar
    Tramer, Federica
    Passamonti, Sabina
    Vrhovsek, Urska
    Ventura, M. Rita
    Brito, Maria Alexandra
    Nunes dos Santos, Claudia
    Figueira, Ines
    FOOD & FUNCTION, 2024, 15 (15) : 7812 - 7827
  • [35] Brain targeting PBCA nanoparticles and the blood-brain barrier
    Wilson, B.
    NANOMEDICINE, 2009, 4 (05) : 499 - 502
  • [36] Intestinal and Blood-Brain Barrier Permeability of Ginkgolides and Bilobalide: In Vitro and In Vivo Approaches
    Madgula, Vamsi L. M.
    Avula, Bharathi
    Yu, Young-Beob
    Wang, Yan-Hong
    Tchantchou, Flaubert
    Fisher, Scott
    Luo, Yuan
    Khan, Ikhlas A.
    Khan, Shabana I.
    PLANTA MEDICA, 2010, 76 (06) : 599 - 606
  • [37] The Permeability of Puerarin Loaded Poly(butylcyanoacrylate) Nanoparticles Coated with Polysorbate 80 on the Blood-Brain Barrier and Its Protective Effect against Cerebral Ischemia/Reperfusion Injury
    Zhao, Li-xia
    Liu, An-chang
    Yu, Shu-wen
    Wang, Zeng-xin
    Lin, Xiao-qian
    Zhai, Guang-xi
    Zhang, Qing-zhu
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (08) : 1263 - 1270
  • [38] In Vitro-In Vivo Extrapolation of Key Transporter Activity at the Blood-Brain Barrier
    Trapa, Patrick E.
    Troutman, Matthew D.
    Lau, Thomas Y.
    Wager, Travis T.
    Maurer, Tristan S.
    Patel, Nandini C.
    West, Mark A.
    Umland, John P.
    Carlo, Anthony A.
    Feng, Bo
    Liras, Jennifer L.
    DRUG METABOLISM AND DISPOSITION, 2019, 47 (04) : 405 - 411
  • [39] Tumor treating fields effects on the blood-brain barrier in vitro and in vivo.
    Salvador, Ellaine
    Kessler, Almuth
    Hoermann, Julia
    Domroese, Dominik
    Schaeffer, Clara
    Burek, Malgorzata
    Tempel-Brami, Catherine
    Voloshin, Tali
    Giladi, Moshe
    Ernestus, Ralf-Ingo
    Loehr, Mario
    Foerster, Carola
    Hagemann, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] An in vivo model of the human blood-brain barrier
    Dallasta, LM
    Sanders, VJ
    Maguire, JL
    Randall, KA
    Achim, CL
    Wiley, CA
    FASEB JOURNAL, 1998, 12 (05): : A668 - A668